Please login to the form below

Not currently logged in
Email:
Password:

Pfizer and Astellas co-promote Caduet

Pfizer Japan and Astellas have agreed to co-promote a combination hypertension and hypercholesterolemia drug in Japan

The treatment, Caduet Combination Tablets, is an oral combination of Pfizer's hypertension treatment, Norvasc (amlodipine besylate) and hypercholesterolemia drug, Lipitor (atorvastatin calcium). The single tablet combination is expected to improve patient adherence.

Under the terms of the agreement (which lasts until July 2016), Pfizer will manufacture the combination treatment and be responsible for sales, while both companies will promote it.

The companies have worked together previously and co-promote Lipitor. Caduet Combination Tablets are approved in more than 70 countries/areas and will be available in Japan once listed on Japan's National Health Insurance drug price list.

26th August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
90TEN Healthcare

90TEN is an award-winning healthcare communications consultancy that puts people at the heart of everything we do. Our Life.Changing. campaigns...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics